ClinicalTrials.gg
CompletedNCT05105841Updated Oct 21, 2026Results posted

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Phase 2 interventional study of Venetoclax and Ibrutinib in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by AbbVie. Completed at 20 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Updated Oct 21, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 8 open to participants now, 28 under way, 4 of them phase 3. ibrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
64th of 83
20 · median 44
Started
2021
with 2 others
Phase 2
43 of 83
6 open now
Registered
77th of 83
by date

Among the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 64th largest by enrollment, is one of 3 that started in 2021, is one of 43 in phase 2, and was the 77th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

8 of the 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing ibrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias. There is a large difference in proportion of malignant lymphoma between the United States (US) and Japan was seen in CLL/small lymphocytic lymphoma (SLL) (Japan, 3.2%; US, 24.1%). The purpose of this study is to assess how well venetoclax works in combination with obinutuzumab (V+G, Cohort 1) or with ibrutinib (V+I, Cohort 2) in Japanese participants with previously untreated CLL/Small Lymphocytic Lymphoma (SLL). Adverse events and change in disease activity will be assessed.

Venetoclax is an approved drug for the treatment of CLL and SLL. Study doctors put the participants in 1 of 2 groups, called treatment arms, based on variable alternating assignment. Approximately 20 adult participants with previously untreated CLL/SLL will be enrolled in the study in approximately 20 sites in Japan.

Participants in group 1 will receive oral venetoclax + intravenous (IV) obinutuzumab (V+G) in 28-day cycles for a total of 12 cycles, and participants in group 2 will receive oral venetoclax + oral ibrutinib (V+I) in 28-day cycles for a total of 15 cycles.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.

03

Conditions studied

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)

Keywords

  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Ibrutinib
  • Imbruvica
  • Venetoclax
  • Venclexta
  • Venclyxto
  • Obinutuzumab
  • GA101
  • Gazyva
  • RO5072759
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or female, at least ≥ 65 years old; or 20 to 64 years old and have at least 1 of the following:

    • Cumulative Illness Rating Scale (CIRS) score > 6.
    • (CrCl) estimated \< 70 mL/min using Cockcroft-Gault equation.
  • Must have measurable nodal disease (by computed tomography [CT]), defined as at least one lymph node > 1.5 cm in longest diameter.
  • Diagnosed Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) that requires treatment according to the Modified 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria.

Exclusion criteria

Exclusion Criteria:

  • Transformation of Chronic Lymphocytic Leukemia (CLL) to aggressive non-Hodgkin lymphoma (NHL; Richter's transformation or pro-lymphocytic leukemia).
  • Previous treatment history for CLL/SLL.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Venetoclax + Obinutuzumab (V+G)

    Participants will receive venetoclax + obinutuzumab for twelve 28-day cycles.

    Drug: Venetoclax · Drug: Obinutuzumab

  • Experimental
    Venetoclax + Ibrutinib (V+I)

    Participants will receive venetoclax + ibrutinib for fifteen 28-day cycles.

    Drug: Venetoclax · Drug: Ibrutinib

Interventions

  • Oral Tablet

    Also known as: Venclexta, ABT-199, GDC-0199

  • Oral Capsule

    Also known as: Imbruvica

  • Intravenous (IV) Infusion

    Also known as: GA101, Gazyva, RO5072759

06

What researchers measure

Primary outcomes

  1. Complete Remission (CR) and CR With an Incomplete Marrow Recovery (CRi) Rate Per Independent Review Committee (IRC)

    CR+CRi rate was defined as the percentage of participants achieving a best response of CR or CRi as assessed by an IRC per 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for tumor response. CR required all of the following: * Group A: * Lymphadenopathy: None \> 1.5 centimeters * Blood Lymphocytes: \<4,000/microliter (μL) * Hepatomegaly: None * Splenomegaly: None * Marrow: Normocellular, \< 30% lymphocytes, no B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL * Hemoglobin: \> 11.0 grams per deciliter (g/dL) * Neutrophils: \> 1500/μL CRi was defined as a CR with peripheral cytopenia and incomplete recovery of the bone marrow, manifested by persistent cytopenias.

    Time frame: Up to 46 months

Secondary outcomes

  1. CR+CRi Rate Per Investigator Assessment

    CR+CRi rate was defined as the percentage of participants achieving a best response of CR or CRi as assessed by an IRC per iwCLL criteria for tumor response. CR required all of the following: * Group A: * Lymphadenopathy: None \> 1.5 centimeters * Blood Lymphocytes: \<4,000/μL * Hepatomegaly: None * Splenomegaly: None * Marrow: Normocellular, \< 30% lymphocytes, no B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL * Hemoglobin: \> 11.0 g/dL * Neutrophils: \> 1500/μL CRi was defined as a CR with peripheral cytopenia and incomplete recovery of the bone marrow, manifested by persistent cytopenias.

    Time frame: Up to 46 months

  2. Overall Response Rate (ORR) Per IRC

    ORR was defined as the percentage of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria. PR required at Least 2 Criteria from Group A AND at least 1 Criterion from Group B: * Group A: * Lymphadenopathy: Decrease ≥ 50% * Blood Lymphocytes: Decrease ≥ 50% from baseline * Hepatomegaly: Decrease ≥ 50% * Splenomegaly: Decrease ≥ 50% * Marrow: 50% reduction in marrow infiltrate or B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL or increase ≥ 50% over baseline * Hemoglobin: \> 11.0 g/dL or increase ≥ 50% over baseline * Neutrophils: \> 1500/μL or increase ≥ 50% over baseline nPR was a response that met the criteria for CR, but the bone marrow biopsy showed lymphoid nodules, reflecting residual disease.

    Time frame: Baseline up to 46 months

  3. ORR Per Investigator Assessment

    ORR was defined as the percentage of participants with a best overall response of CR, CRi, PR or nPR per 2008 iwCLL criteria.

    Time frame: Baseline up to 46 months

  4. Progression-Free Survival (PFS) Per IRC

    PFS was defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurred first, according to iwCLL criteria. PFS was analyzed using Kaplan-Meier methodology.

    Time frame: Up to 46 months

  5. PFS Per Investigator Assessment

    PFS was defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurred first, according to iwCLL criteria. PFS was analyzed using Kaplan-Meier methodology.

    Time frame: Up to 46 months

  6. Duration of Response (DOR) as Assessed by IRC

    DOR was defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurred first, as determined by an IRC according to iwCLL criteria.

    Time frame: Up to 46 months

  7. DOR as Assessed by Investigator

    DOR was defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurred first, as determined by an IRC according to iwCLL criteria.

    Time frame: Up to 46 months

  8. Overall Survival (OS)

    OS was defined as the time from the date of the first dose of any study drug until death due to any cause.

    Time frame: Up to 46 months

  9. Time to Progression (TTP) as Assessed by IRC

    TTP was defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an IRC according to iwCLL criteria.

    Time frame: Up to 46 months

  10. TTP as Assessed by Investigator

    TTP was defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an investigator according to iwCLL criteria.

    Time frame: Up to 46 months

07

Results

Posted Oct 21, 2026

Participant flow

Participant flow — Overall Study
MilestoneVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
Started1010
Received at least 1 dose of study drug1010
Completed1010
Not completed00

Outcome measures

PrimaryComplete Remission (CR) and CR With an Incomplete Marrow Recovery (CRi) Rate Per Independent Review Committee (IRC)

CR+CRi rate was defined as the percentage of participants achieving a best response of CR or CRi as assessed by an IRC per 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for tumor response. CR required all of the following: * Group A: * Lymphadenopathy: None \> 1.5 centimeters * Blood Lymphocytes: \<4,000/microliter (μL) * Hepatomegaly: None * Splenomegaly: None * Marrow: Normocellular, \< 30% lymphocytes, no B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL * Hemoglobin: \> 11.0 grams per deciliter (g/dL) * Neutrophils: \> 1500/μL CRi was defined as a CR with peripheral cytopenia and incomplete recovery of the bone marrow, manifested by persistent cytopenias.

Time frame:
Up to 46 months
Reported as:
Number · percentage of participants
Complete Remission (CR) and CR With an Incomplete Marrow Recovery (CRi) Rate Per Independent Review Committee (IRC)
percentage of participantsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
Complete Remission (CR) and CR With an Incomplete Marrow Recovery (CRi) Rate Per Independent Review Committee (IRC)100 (69.2 to 100.0)80.0 (44.4 to 97.5)
SecondaryCR+CRi Rate Per Investigator Assessment

CR+CRi rate was defined as the percentage of participants achieving a best response of CR or CRi as assessed by an IRC per iwCLL criteria for tumor response. CR required all of the following: * Group A: * Lymphadenopathy: None \> 1.5 centimeters * Blood Lymphocytes: \<4,000/μL * Hepatomegaly: None * Splenomegaly: None * Marrow: Normocellular, \< 30% lymphocytes, no B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL * Hemoglobin: \> 11.0 g/dL * Neutrophils: \> 1500/μL CRi was defined as a CR with peripheral cytopenia and incomplete recovery of the bone marrow, manifested by persistent cytopenias.

Time frame:
Up to 46 months
Reported as:
Number · percentage of participants
CR+CRi Rate Per Investigator Assessment
percentage of participantsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
CR+CRi Rate Per Investigator Assessment90.0 (55.5 to 99.7)60.0 (26.2 to 87.8)
SecondaryOverall Response Rate (ORR) Per IRC

ORR was defined as the percentage of participants with a best overall response of CR, CRi, partial remission (PR) or nodular partial remission (nPR) per 2008 iwCLL criteria. PR required at Least 2 Criteria from Group A AND at least 1 Criterion from Group B: * Group A: * Lymphadenopathy: Decrease ≥ 50% * Blood Lymphocytes: Decrease ≥ 50% from baseline * Hepatomegaly: Decrease ≥ 50% * Splenomegaly: Decrease ≥ 50% * Marrow: 50% reduction in marrow infiltrate or B-lymphoid nodules * Group B: * Platelet Count: \> 100,000/μL or increase ≥ 50% over baseline * Hemoglobin: \> 11.0 g/dL or increase ≥ 50% over baseline * Neutrophils: \> 1500/μL or increase ≥ 50% over baseline nPR was a response that met the criteria for CR, but the bone marrow biopsy showed lymphoid nodules, reflecting residual disease.

Time frame:
Baseline up to 46 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Per IRC
percentage of participantsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
Overall Response Rate (ORR) Per IRC100 (69.2 to 100.0)100 (69.2 to 100.0)
SecondaryORR Per Investigator Assessment

ORR was defined as the percentage of participants with a best overall response of CR, CRi, PR or nPR per 2008 iwCLL criteria.

Time frame:
Baseline up to 46 months
Reported as:
Number · percentage of participants
ORR Per Investigator Assessment
percentage of participantsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
ORR Per Investigator Assessment100 (69.2 to 100.0)90.0 (55.5 to 99.7)
SecondaryProgression-Free Survival (PFS) Per IRC

PFS was defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurred first, according to iwCLL criteria. PFS was analyzed using Kaplan-Meier methodology.

Time frame:
Up to 46 months
Reported as:
Median · months
Progression-Free Survival (PFS) Per IRC
monthsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
Progression-Free Survival (PFS) Per IRCNA (NA to NA)NA (24.6 to NA)
SecondaryPFS Per Investigator Assessment

PFS was defined as the time from the date of first dose of any study drug until the date of disease progression or death due to any cause, whichever occurred first, according to iwCLL criteria. PFS was analyzed using Kaplan-Meier methodology.

Time frame:
Up to 46 months
Reported as:
Median · months
PFS Per Investigator Assessment
monthsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
PFS Per Investigator AssessmentNA (NA to NA)31.0 (16.2 to NA)
SecondaryDuration of Response (DOR) as Assessed by IRC

DOR was defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurred first, as determined by an IRC according to iwCLL criteria.

Time frame:
Up to 46 months
Reported as:
Median · months
Duration of Response (DOR) as Assessed by IRC
monthsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
Duration of Response (DOR) as Assessed by IRCNA (NA to NA)NA (17.3 to NA)
SecondaryDOR as Assessed by Investigator

DOR was defined as the time from the first occurrence of overall response (CR, CRi, PR or nPR) until disease progression or death due to any cause, whichever occurred first, as determined by an IRC according to iwCLL criteria.

Time frame:
Up to 46 months
Reported as:
Median · months
DOR as Assessed by Investigator
monthsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
DOR as Assessed by InvestigatorNA (NA to NA)NA (7.7 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of the first dose of any study drug until death due to any cause.

Time frame:
Up to 46 months
Reported as:
Median · months
Overall Survival (OS)
monthsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryTime to Progression (TTP) as Assessed by IRC

TTP was defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an IRC according to iwCLL criteria.

Time frame:
Up to 46 months
Reported as:
Median · months
Time to Progression (TTP) as Assessed by IRC
monthsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
Time to Progression (TTP) as Assessed by IRCNA (NA to NA)NA (24.6 to NA)
SecondaryTTP as Assessed by Investigator

TTP was defined as the time from the date of first dose of any study drug until the date of disease progression, as determined by an investigator according to iwCLL criteria.

Time frame:
Up to 46 months
Reported as:
Median · months
TTP as Assessed by Investigator
monthsVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
TTP as Assessed by InvestigatorNA (NA to NA)31.0 (16.2 to NA)

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection to the end of the study. The median time on follow-up was 1134.5 and 1172.5 days for arms Venetoclax + Obinutuzumab and Venetoclax + Ibrutinib respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Venetoclax + Obinutuzumab0/10 (0%)5/10 (50%)10/10 (100%)
Venetoclax + Ibrutinib0/10 (0%)3/10 (30%)10/10 (100%)
Most frequent serious events
Most frequent serious events
EventVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
FEBRILE NEUTROPENIABlood and lymphatic system disorders1/101/10
ATRIAL FIBRILLATIONCardiac disorders0/101/10
MACULAR HOLEEye disorders1/100/10
ABSCESS LIMBInfections and infestations0/101/10
COVID-19Infections and infestations0/101/10
HEPATITIS B REACTIVATIONInfections and infestations1/100/10
PNEUMONIA BACTERIALInfections and infestations1/100/10
PNEUMONIA MYCOPLASMALInfections and infestations1/100/10
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations0/101/10
URETEROLITHIASISRenal and urinary disorders1/100/10
Most frequent other events
Showing 10 of 114
Most frequent other events
EventVenetoclax + ObinutuzumabVenetoclax + Ibrutinib
INFUSION RELATED REACTIONInjury, poisoning and procedural complications6/100/10
NEUTROPHIL COUNT DECREASEDInvestigations5/104/10
RASHSkin and subcutaneous tissue disorders0/105/10
DIARRHOEAGastrointestinal disorders3/104/10
NAUSEAGastrointestinal disorders4/104/10
PYREXIAGeneral disorders4/100/10
COVID-19Infections and infestations4/102/10
ANAEMIABlood and lymphatic system disorders3/101/10
LEUKOPENIABlood and lymphatic system disorders3/100/10
LYMPHOPENIABlood and lymphatic system disorders3/101/10

Baseline characteristics

The full analysis set (FAS) included all participants who received at least 1 dose of study drug.

Age, Categorical
Age, Categorical(Participants)Venetoclax + ObinutuzumabVenetoclax + IbrutinibTotal
<=18 years000
Between 18 and 65 years415
>=65 years6915
Sex: Female, Male
Sex: Female, Male(Participants)Venetoclax + ObinutuzumabVenetoclax + IbrutinibTotal
Female448
Male6612
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Venetoclax + ObinutuzumabVenetoclax + IbrutinibTotal
American Indian or Alaska Native000
Asian101020
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Venetoclax + ObinutuzumabVenetoclax + IbrutinibTotal
Japanese101020
Chinese000
Korean000
Taiwanese000
Other000
08

Study locations

20 sites
  • NHO Nagoya Medical Center /ID# 233523
    Nagoya, Aichi-ken 460-0001, Japan
  • Aichi Cancer Center Hospital /ID# 238797
    Nagoya, Aichi-ken 464-8681, Japan
  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524
    Nagoya, Aichi-ken 466-8650, Japan
  • Chiba Cancer Center /ID# 238839
    Chiba, Chiba 260-8717, Japan
  • National Hospital Organization Shikoku Cancer Center /ID# 234059
    Matsuyama, Ehime 791-0280, Japan
  • Kyushu University Hospital /ID# 238437
    Fukuoka, Fukuoka 812-8582, Japan
  • Hokkaido University Hospital /ID# 238377
    Sapporo, Hokkaido 060-8648, Japan
  • Hyogo Prefectural Amagasaki General Medical Center /ID# 234082
    Amagasaki-shi, Hyōgo 660-8550, Japan
  • Tokai University Hospital /ID# 238970
    Isehara, Kanagawa 259-1193, Japan
  • University Hospital Kyoto Prefectural University of Medicine /ID# 239883
    Kyoto, Kyoto 602-8566, Japan
  • Tohoku University Hospital /ID# 238433
    Sendai, Miyagi 9808574, Japan
  • Niigata University Medical & Dental Hospital /ID# 238324
    Niigata, Niigata 951-8520, Japan
  • Okayama University Hospital /ID# 238467
    Okayama, Okayama-ken 700-8558, Japan
  • Kindai University Hospital /ID# 234001
    Sakai-shi, Osaka 590-0197, Japan
  • Osaka University Hospital /ID# 234037
    Suita-shi, Osaka 565-0871, Japan
  • Shimane University Hospital /ID# 234076
    Izumo-shi, Shimane 693-8501, Japan
  • Jichi Medical University Hospital /ID# 238434
    Shimotsuke-shi, Tochigi 329-0498, Japan
  • National Cancer Center Hospital /ID# 232449
    Chuo-ku, Tokyo 104-0045, Japan
  • The Cancer Institute Hospital Of JFCR /ID# 232450
    Koto-ku, Tokyo 135-8550, Japan
  • Yamagata University Hospital /ID# 234032
    Yamagata, Yamagata 990-9585, Japan
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Oct 2025, 47 months.

Results were first posted in Oct 2026, 1 year after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 47 months is below that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2021
First posted
Nov 3, 2021
StartActual
Nov 8, 2021
Primary completionActual
Oct 9, 2025
CompletionActual
Oct 9, 2025
Results first posted
Oct 21, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 21, 2026
Sites
9 sites added, 9 sites removed
Show 9 added (9 Japan)
  • NHO Nagoya Medical Center /ID# 233523 · Nagoya, Japan
  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524 · Nagoya, Japan
  • Chiba Cancer Center /ID# 238839 · Chiba, Japan
  • Hokkaido University Hospital /ID# 238377 · Sapporo, Japan
  • Okayama University Hospital /ID# 238467 · Okayama, Japan
  • Kindai University Hospital /ID# 234001 · Sakai-shi, Japan
  • Osaka University Hospital /ID# 234037 · Suita-shi, Japan
  • Shimane University Hospital /ID# 234076 · Izumo-shi, Japan
  • Jichi Medical University Hospital /ID# 238434 · Shimotsuke-shi, Japan
Show 9 removed
  • Duplicate_NHO Nagoya Medical Center /ID# 233523 · Nagoya, Japan
  • Duplicate_Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524 · Nagoya, Japan
  • Duplicate_Chiba Cancer Center /ID# 238839 · Chiba, Japan
  • Duplicate_Hokkaido University Hospital /ID# 238377 · Sapporo, Japan
  • Duplicate_Okayama University Hospital /ID# 238467 · Okayama, Japan
  • Kindai University Hospital /ID# 234001 · Osakasayama-shi, Japan
  • Duplicate_Osaka University Hospital /ID# 234037 · Suita-shi, Japan
  • Duplicate_Shimane University Hospital /ID# 234076 · Izumo-shi, Japan
  • Duplicate_Jichi Medical University Hospital /ID# 238434 · Shimotsuke-shi, Japan
Oct 21, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • EditedComplete Remission (CR) withand CR With an Incomplete Marrow Recovery (CRi) Rate, as Assessed by an Per Independent Review Committee (IRC) per Modified 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) for Venetoclax + Obinutuzumab (V+G)Time frame: Up to Week 32 → Up to 46 months
  • RemovedCR/CRi Rate, as Assessed by an IRC per iwCLL for Venetoclax + Ibrutinib (V+I)Time frame: Up to Week 56
Oct 21, 2026
Documents
Secondary outcomes
7 edited, 3 added, 13 removed
What changed in the outcomes
  • EditedOverall response rateResponse Rate (ORR) as Assessed byPer IRC for (V+G)Time frame: Up to Week 32 → Baseline up to 46 months
  • EditedORRDOR as Assessed by Investigator for (V+G)Time frame: Up to Week 32 → Up to 46 months
  • EditedProgression-Free Survival (PFS) as Assessed byPer IRC for (V+G)Time frame: Up to Week 32 → Up to 46 months
  • EditedPFSTTP as Assessed by Investigator for (V+G)Time frame: Up to Week 32 → Up to 46 months
  • EditedDuration of responseResponse (DOR) as Assessed by IRC for (V+G)Time frame: Up to Week 32 → Up to 46 months
  • EditedOverall Survival (OS) for (V+G)Time frame: Up to Week 32 → Up to 46 months
  • EditedTime to progressionProgression (TTP) as Assessed by IRC for (V+G)Time frame: Up to Week 32 → Up to 46 months
  • AddedCR+CRi Rate Per Investigator AssessmentTime frame: Up to 46 months
  • AddedORR Per Investigator AssessmentTime frame: Baseline up to 46 months
  • AddedPFS Per Investigator AssessmentTime frame: Up to 46 months
  • RemovedCR/CRi Rate, as Assessed by an Investigator per iwCLL for (V+G)Time frame: Up to Week 32
  • RemovedCR/CRi Rate, as Assessed by an Investigator per iwCLL for (V+I)Time frame: Up to Week 56
  • RemovedORR as Assessed by IRC (V+I)Time frame: Up to Week 56
  • RemovedORR Assessed by Investigator + Ibrutinib (V+I)Time frame: Up to Week 56
  • RemovedPFS as Assessed by IRC for (V+I)Time frame: Up to Week 56
  • RemovedPFS as Assessed by Investigator for (V+I)Time frame: Up to Week 56
  • RemovedDOR as Assessed by IRC for (V+I)Time frame: Up to Week 56
  • RemovedDOR as Assessed by Investigator for (V+G)Time frame: Up to Week 32
  • RemovedDOR as Assessed by Investigator for (V+I)Time frame: Up to Week 56
  • RemovedOS for (V+I)Time frame: Up to Week 56
  • RemovedTTP as Assessed by IRC for (V+I)Time frame: Up to Week 56
  • RemovedTTP as Assessed by Investigator for (V+G)Time frame: Up to Week 32
  • RemovedTTP as Assessed by Investigator for (V+I)Time frame: Up to Week 56
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    Results posted
    9 sites added, 9 sites removed
    Show 9 added (9 Japan)
    • NHO Nagoya Medical Center /ID# 233523 · Nagoya, Japan
    • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524 · Nagoya, Japan
    • Chiba Cancer Center /ID# 238839 · Chiba, Japan
    • Hokkaido University Hospital /ID# 238377 · Sapporo, Japan
    • Okayama University Hospital /ID# 238467 · Okayama, Japan
    • Kindai University Hospital /ID# 234001 · Sakai-shi, Japan
    • Osaka University Hospital /ID# 234037 · Suita-shi, Japan
    • Shimane University Hospital /ID# 234076 · Izumo-shi, Japan
    • Jichi Medical University Hospital /ID# 238434 · Shimotsuke-shi, Japan
    Show 9 removed
    • Duplicate_NHO Nagoya Medical Center /ID# 233523 · Nagoya, Japan
    • Duplicate_Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524 · Nagoya, Japan
    • Duplicate_Chiba Cancer Center /ID# 238839 · Chiba, Japan
    • Duplicate_Hokkaido University Hospital /ID# 238377 · Sapporo, Japan
    • Duplicate_Okayama University Hospital /ID# 238467 · Okayama, Japan
    • Kindai University Hospital /ID# 234001 · Osakasayama-shi, Japan
    • Duplicate_Osaka University Hospital /ID# 234037 · Suita-shi, Japan
    • Duplicate_Shimane University Hospital /ID# 234076 · Izumo-shi, Japan
    • Duplicate_Jichi Medical University Hospital /ID# 238434 · Shimotsuke-shi, Japan
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • EditedComplete Remission (CR) withand CR With an Incomplete Marrow Recovery (CRi) Rate, as Assessed by an Per Independent Review Committee (IRC) per Modified 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) for Venetoclax + Obinutuzumab (V+G)Time frame: Up to Week 32 → Up to 46 months
    • RemovedCR/CRi Rate, as Assessed by an IRC per iwCLL for Venetoclax + Ibrutinib (V+I)Time frame: Up to Week 56
    Secondary outcomes 7 edited, 3 added, 13 removed
    What changed in the outcomes
    • EditedOverall response rateResponse Rate (ORR) as Assessed byPer IRC for (V+G)Time frame: Up to Week 32 → Baseline up to 46 months
    • EditedORRDOR as Assessed by Investigator for (V+G)Time frame: Up to Week 32 → Up to 46 months
    • EditedProgression-Free Survival (PFS) as Assessed byPer IRC for (V+G)Time frame: Up to Week 32 → Up to 46 months
    • EditedPFSTTP as Assessed by Investigator for (V+G)Time frame: Up to Week 32 → Up to 46 months
    • EditedDuration of responseResponse (DOR) as Assessed by IRC for (V+G)Time frame: Up to Week 32 → Up to 46 months
    • EditedOverall Survival (OS) for (V+G)Time frame: Up to Week 32 → Up to 46 months
    • EditedTime to progressionProgression (TTP) as Assessed by IRC for (V+G)Time frame: Up to Week 32 → Up to 46 months
    • AddedCR+CRi Rate Per Investigator AssessmentTime frame: Up to 46 months
    • AddedORR Per Investigator AssessmentTime frame: Baseline up to 46 months
    • AddedPFS Per Investigator AssessmentTime frame: Up to 46 months
    • RemovedCR/CRi Rate, as Assessed by an Investigator per iwCLL for (V+G)Time frame: Up to Week 32
    • RemovedCR/CRi Rate, as Assessed by an Investigator per iwCLL for (V+I)Time frame: Up to Week 56
    • RemovedORR as Assessed by IRC (V+I)Time frame: Up to Week 56
    • RemovedORR Assessed by Investigator + Ibrutinib (V+I)Time frame: Up to Week 56
    • RemovedPFS as Assessed by IRC for (V+I)Time frame: Up to Week 56
    • RemovedPFS as Assessed by Investigator for (V+I)Time frame: Up to Week 56
    • RemovedDOR as Assessed by IRC for (V+I)Time frame: Up to Week 56
    • RemovedDOR as Assessed by Investigator for (V+G)Time frame: Up to Week 32
    • RemovedDOR as Assessed by Investigator for (V+I)Time frame: Up to Week 56
    • RemovedOS for (V+I)Time frame: Up to Week 56
    • RemovedTTP as Assessed by IRC for (V+I)Time frame: Up to Week 56
    • RemovedTTP as Assessed by Investigator for (V+G)Time frame: Up to Week 32
    • RemovedTTP as Assessed by Investigator for (V+I)Time frame: Up to Week 56
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05105841
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Nov 8, 2021
Primary completion
Oct 9, 2025
Completion
Oct 9, 2025
Results posted
Oct 21, 2026
Last update
Oct 21, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Obinutuzumab

Start the discussion